(UroToday.com) Renowned testis cancer expert Dr. Peter Albers discussed personalized therapy to reduce treatment morbidity in testicular cancer at the rare tumors session of the European Association of Urology (EAU) Section of Oncological Urology (ESOU) 2021 Virtual meeting. Dr. Albers highlights that testicular cancer survivorship is heterogeneous across Europe ranging from 80% in Eastern Europe to 92% in Central Europe. As such, new problems have arisen over decades of testicular cancer survivors, including second malignancies and toxic deaths (ie. cardiovascular) as a result of treatment. According to Dr. Albers, there are 3 areas that need to be addressed in order to reduce treatment morbidity associated with testicular cancer: